Veradermics Q2 FY26 net loss widens to $23.5 million; R&D expense rises to $18.61 million

Reuters2026/08/11 11:30

Bitget offers one-stop trading for cryptocurrencies, stocks, and gold. Trade now!

A welcome pack worth 6200 USDT for new users! Sign up now!

Veradermics posted a GAAP net loss of USD 23.5 million in Q2 2026, widening from USD 15.6 million a year earlier.
RD expenses rose to USD 18.6 million from USD 14.3 million, due to higher VDPHL01 development spending and personnel costs.
GA expenses climbed to USD 10.9 million from USD 1.7 million, on higher headcount, stock-based compensation, and commercial readiness costs.
Cash, cash equivalents and marketable securities totaled USD 819.9 million at June 30, expected to fund operations into 2030.
Completed enrollment in 556-patient female hair-loss Study 306; Phase 3 male Study 304 topline data due 2H26, female Study 306 topline due 1H27.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Veradermics Inc. published the original content used to generate this news brief via Business Wire (Ref. ID: 202608110730BIZWIRE_USPR_____20260811_BW850534) on August 11, 2026, and is solely responsible for the information contained therein.

Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.

Understand the market, then trade.

Bitget offers one-stop trading for cryptocurrencies, stocks, and gold.

Trade now！

Veradermics Q2 FY26 net loss widens to $23.5 million; R&D expense rises to $18.61 million

You may also like

Crypto prices